Synbody Biotechnology (SBI) is a start-up biotechnology company based on a powerful synthetic antibody, or 'Synbody,' technology recently discovered at Arizona State University. Synbodies revolutionize the field of high affinity, high specificity therapeutic agents by creating antibody-like function from small purely synthetic peptides. It is SBI's mission to leverage the Synbody technology to create a pipeline of superior human therapeutics across multiple therapeutic areas. SBI seeks to realize the opportunity for synbodies as human therapeutics through a combined strategy comprising corporate partnerships, out-licensing agreements and in-house development.
